… Filip YFL de Vos, MD Filip YFL de Vos … Department of Medical Oncology & Clinical
Research Unit, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Since Folkman defined angiogenesis more than 25 years ago as the most important process
in tumour growth and metastasis, specific anti-angiogenic agents have been developed. …

Breast cancer is the most common malignancy amongst women in the developed world. For
patients with hormone-sensitive breast cancer eligible for adjuvant hormonal therapy, it is …

Aims Methylation profiling (MP) is increasingly incorporated in the diagnostic process of
central nervous system (CNS) tumours at our centres in The Netherlands and Scandinavia. We …

Background Palliative systematic treatment offers uncertain and often limited benefits, and
the burden can be high. Hence, treatment decisions require shared decision making (SDM). …

Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary
embolism (PE), frequently complicates the postoperative course of primary malignant brain …

Background Systemic treatment for advanced cancer offers uncertain and sometimes limited
benefit, while the burden can be high. This study examines the effect of shared decision‐…

Purpose ABT-510 is an angiogenesis inhibitor derived from thrombospondin-1, a naturally
occurring inhibitor of angiogenesis. We investigated ABT-510, which was administered …

… Filip YFL de Vos … Because a 5 day on/2 day off regimen was considered preferential, this
regimen was maintained, and PD-0325901 was de-escalated to 5 mg of PD-… Filip YFL de Vos …